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Abstract
Background: Cordyceps taii, an entomogenous fungus native to south China, is a folk medicine with varieties of
pharmacological activities including anticancer effect. To validate the ethnopharmacological claim against cancer,
the antitumor and antimetastatic activities of chloroform extract of C. taii (CFCT) were investigated in vivo.
Methods: The in vitro cytotoxic activities of CFCT against human lung cancer (A549) and gastric cancer (SGC-7901)
cells were evaluated using the Sulforhodamine B (SRB) assay. In vivo anti tumor and antimetastatic activities,
Kunming mice bearing sarcoma 180 and C57BL/6 mice bearing melanoma B16F10 were employed, respectively.
The antitumor effects of CFCT were completely evaluated on the basis of the tumor weight, survival time, histologic
analysis, and immune organ indices. The histopathological change, metastatic foci and malignant melanoma
specific marker HMB45 in the lung tissue were detected for the evaluation of the antimetastatic activity of CFCT.
Results: CFCT exhibited dose- and time-dependent cytotoxicities against A549 and SGC-7901 cells with the IC50
values of 30.2 and 65.7 μg/mL, respectively. Furthermore, CFCT at a dose of 50 or 100 mg/kg could significantly in-
hibit the tumor growth in vivo and prolonged the survival time in two different models as compared with the
model group, especially when combined with the CTX at a low dose rate. And it also increased spleen index of
Kunming mice and thymus index of C57BL/6 mice. Meanwhile, histologic analysis illustrated that CFCT alone or in
combination with CTX could induce tumor tissue necrosis of both models. In addition, CFCT at a dose of 50 or
100 mg/kg inhibited the lung metastasis of melanoma B16F10 in tumor-bearing C57BL/6 mice. The antimetastatic
effect was also observed when CFCT was used in combination with CTX. In comparison to any other groups, CFCT
at a dose of 100 mg/kg could effectively enhance the GSH-Px activities of various tissues in tumor-bearing C57BL/6
mice.
Conclusions: These findings demonstrate that CFCT has potent in vivo antitumor and antimetastatic activities, and
may be helpful to the development of anticancer chemopreventive agents from C. taii.
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Background
Due to substantial morbidity and high mortality, cancer is
considered as the second “killer” in the world [1]. A latest
global cancer trend report by the World Health
Organization shows that new cancer cases worldwide will
remain a rapid increase, and reach more than 19 million a
year by 2025 [2]. Cancer is a major global health crisis ac-
cordingly, and urgently needs effective prevention mea-
sures to curb the disease. Although the development of
biological therapies have been used as new strategies for
cancer treatment in recent years, surgery, radiotherapy
and chemotherapy are still the three most frequently used
therapies in the world. In comparison with surgery and
radiotherapy, chemotherapy possess some advantages like
systemic treatment and not causing significant physical
damage, and it is recommended for patients with extrapel-
vic metastases or recurrent disease who are not candidates
for the other two treatments [3]. However, long-term use
of single-agent or combination chemotherapy usually
results in severe side effects and resistance [4]. Obviously
there is an urgent demand for exploring new chemother-
apy drugs with high efficiency and low toxicity. The dis-
covery of taxol and camptothecin lights up the hope for
searching new anticancer drugs from natural sources.
The genus Cordyceps, an entomogenous fungus with a
wide variety of pharmacological properties, is a well-known
and valuable source of traditional Chinese medicine. The
applications of Cordyceps in China and other Eastern Asian
countries suggest that it may be used for cancer prevention
and treatment [5]. Furthermore, current Cordyceps has re-
ceived considerable attention worldwide as a potential
source of anticancer drugs [6, 7]. Cordyceps taii is a folk
medicine native to south China [8]. Previously, polysaccha-
rides from C. taii were found to display immunomodula-
tory, antitumor, and antimutagenic activities [8]. Our recent
findings suggest that C. taii polysaccharides are a promising
source of natural antioxidant and antiaging agents [9]. Fur-
ther pharmacological experiments indicate that C. taii has
broad-spectrum antimicrobial effects including potent anti-
bacterial and antifungal activities, and the active ingredients
were found to be enriched in non-polar fractions extracted
with organic solvents such as chloroform, ethyl acetate, and
acetone [10, 11]. However, the anticancer potential of these
non-polar fractions of C. taii has never been investigated.
In view of the broad spectrum of therapeutic potentials of
Cordyceps spp., the aim of the present study was to assess
the antitumor and antimetastatic activities of chloroform
extract of C. taii (CFCT) in vivo, and to promote the further
development of anticancer active ingredients from C. taii.
Methods
Chemicals and reagents
Dimethylsulfoxide (DMSO), sulforhodamine B (SRB),
Tris, trypsin, and trypan blue were purchased from
Sigma-Aldrich (USA). The RPMI-1640 medium, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
L-glutamine, and fetal calf serum were purchased from
Gibco (USA). Cyclophosphamide (CTX) was purchased
from Hengrui Pharmaceuticals, Co. Ltd. (Nanjing, China).
Olive oil was purchased from Zhongqi Huaye Inc. (Beijing,
China). Histo-clear agent was purchased from ESM Inc.
(USA). HMB45 anti-melanoma antibody was purchased
from Abcam, PV-6002 non-biotin two-step IHC detection
kit (Horseradish peroxidase-conjugated goat antimouse
IgG secondary antibody) was supplied by Zhongshan
Golden Bridge Biotechnol. Co. Ltd. (Beijing, China), DAB
Horseradish Peroxidase Color Development Kit was pur-
chased from Beyotime Ins. Biotechnol (Haimen, China).
Glutathione peroxidase (GSH-Px) antioxidative enzyme
detection kit was from Jiancheng Bioengin Ins (Nanjing,
China). All chemicals used were of analytic grade.
Medicinal fungus, cultivation, and mycelia preparation
The voucher specimens of C. taii (strain GYYA 0601) were
deposited at the Laboratory of Microbial Resources &
Drug Development, Center for Translational Medicine,
Affiliated Hospital of Zunyi Medical University, Guizhou
Province, China. The mycelia of C. taii were cultured and
harvested as previously described [12, 13]. Subsequently,
the mycelia were lyophilized and grinded (60 mesh to
100 mesh) for later experiments.
Preparation of active fraction
The dried mycelia power of C. taii (4400 g) was ex-
tracted five times with 25 L of 80 % (v/v) aqueous-
methanol solution by hot soaking. The collected extract
solutions were filtered through a 0.45 μm pore-size filter,
and their solvents were then removed at 40 °C by a ro-
tary evaporator under vacumm to yield a brown MeOH
extract (2252 g). Subsequently, the extract was resus-
pended in hot water. The suspension was extracted five
times with equal volumes of petroleum ether (b.p.60–90°)
to yield the petroleum ether extract, and the aqueous resi-
due was further extracted five times with equal volumes of
chloroform. Finally, the combined chloroform layers were
evaporated using a rotary evaporator under reduced pres-
sure to yield the chloroform extract of C. taii (CFCT,
210 g). Stock solution of CFCT was prepared in DMSO
and stored at −20 °C. Further dilution was made with
medium just before use, and the final concentration of
DMSO was less than 0.1 % (v/v).
Cell line and culture
The human lung cancer cell line A549, gastric cancer
cell line SGC-7901, and the mice cancer cell lines such
as sarcoma 180 and melanoma B16F10 were purchased
from the Cell Bank of Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). All the
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above four cell lines were grown in RPMI 1640 medium
supplemented with 10 % fetal bovine serum, 25 mM
HEPES buffer, and 2 mML-glutamine in a humidified
incubator (Thermo, USA) preset to 37 °C and 5 % CO2.
Cells at the logarithmic growth stage were used for all
experiments.
Animals
Kunming (KM) mice and C57BL/6 mice (male; age: 5 to
7 weeks; weight: 18.0 ± 2.0 g) were provided by the Expe-
rimental Animal Center of the Third Military Medical Uni-
versity in Chongqing, China (Animal License No. SCXK
(YU) 2007–2006). The animals were kept in a standard la-
boratory environment and fed with sterile pellets and water
ad libitum. The laboratory animal protocol for this study
was approved by the Zunyi Medical College Committee
for the Control and Supervision of Experimental Animals.
All experimental animals were bred for 7 d before use.
Assay of cytotoxic activity
The SRB colorimetric method was employed, as previously
described, to measure the cytotoxic activities of CFCT
against human cancer cells, including the dose- and time-
responses [14]. CFCT was dissolved in DMSO and stored
at −20 °C. The thawed samples were immediately diluted in
RPMI 1640 medium to reach a concentration of 1 mg/mL
before further use. For the analysis of the dose–response,
cancer cells were seeded into 96-well plates at a density of
6 × 103 cells in 100 μL complete medium per well and were
incubated at 37 °C for 24 h. Eight concentrations of CFCT
(100 μL) were added to each well, and the final concen-
trations were 1.9, 3.9, 7.8, 15.6, 31.25, 62.5, 125.0, and
250.0 μg/mL, respectively. These samples were further in-
cubated for 48 h. A blank control group (culture media
only), a negative control group (cells cultured in the media),
a positive control group (cells were treated with 25 μg/mL
DDP), and a solvent control group (cells treated with
DMSO at the same concentration as the treatment drug
group) were all placed in the same 96-well plate. After 48 h
of drug exposure, its cytotoxic effect was detected using a
SRB colorimetric method as previously reported [14]. The
absorbance data were exported into a Microsoft Excel
spreadsheet (Microsoft) for further analysis. Cell densities
were obtained by correcting the absorbance based on the
blank controls. Cell survival and/or cell growth inhibitory
rate was calculated as the percentage absorbance compared
with that of the negative control. Likewise, cancer cells were
exposed to 40 μg/mL of CFCT for 8, 20, 32, 44, 56, 68 and
76 h, respectively, for analysis of the time response.
Antitumor activity of CFCT in subcutaneous sarcoma
180-bearing mice
The sarcoma-180 (S180) solid tumor model was empo-
lyed to assess the antitumor effect of the CFCT in vivo
on the basis of the tumor growth and host survival.
Tumor cells were harvested from the peritoneal cavity of
KM mice with a 10-day-old S180 ascitic tumor under
the sterile condition, washed twice with sterile saline,
and suspended in the sterile saline at a density of 1 × 107
cells/mL. KM mice were then inoculated subcutaneously
(s.c.) 0.2 mL of tumor cells suspension per mouse into
their right hind limbs on day 0. Subsequently, the mice
were randomly divided into seven groups (n = 16). CFCT
was dissolved in a certain amount of olive oil. The CFCT
treatment groups were administered i.p. daily to the
mice at doses of 20, 50 and 100 mg/kg (LG, MG and HG
groups) for 7 consecutive days, starting 24 h after tumor
transplantation. A combined administration group (CG
group, 20 mg/kg of CFCT + 20 mg/kg of CTX, once daily),
a positive control group (PG group, 20 mg/kg of CTX,
once daily), and a negative control group (SG group, mice
were treated with olive oil at the same volume as the
CFCT treatment group) were also employed on the same
schedule. The Model group was treated with saline only.
The tumor size was measured with digital calipers every
day, and its volume (cm3) was calculated as the (length ×
width2)/2. Two independent experiments were performed
for each treatment with eight mice per group. On day 8,
eight mice from each group were anaesthetized and sacri-
ficed by cervical dislocation, and their bodies were
weighed. Simultaneously, their solid tumor, thymus and
spleen were quickly removed and weighted, respectively.
The tumors were fixed in 10 % paraformaldehyde for at
least 24 h, and then were embedded in paraffin under vac-
cum. While the rest were allowed to live to a natural
death, and the death time was recorded to calculate the
median survival time (MST). The percentage increase in
life span (ILS) of tumor hosts was calculated on the basis
of mortality of the experimental mice: MST = ΣSurvival
time of each mouse in a group/Total number of mice;
%ILS = (MST of treated group/MST of control group) ×
100. The immune organ indices were defined as the thy-
mus and/or spleen weight relative to body weight. Spleen
(thymus) index = Spleen (thymus) weight/body weight ×
100 %. The tumor inhibitory ratio = (the average tumor
weight of model group - the average tumor weight of
treatment group)/the average tumor weight of model
group × 100 %.
Antitumor and antimetastatic activities of CFCT in
subcutaneous melanoma B16F10-bearing mice
Cultured murine melanoma B16F10 cells during the ex-
ponential phase of growth were harvested by trypsiniza-
tion, washed, and suspended at 1.5 × 106 cells/mL in
RPMI-1640 medium supplemented with 10 % FBS.
C57BL/6 mice (n = 112) were injected s.c. with 2.25 ×
105 B16F10 cells per mouse into the lower right groin
on day 0, and were then randomly assigned into seven
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groups (n = 16). After the implantation of tumor, 0.2 mL
CFCT (20, 50 and 100 mg/kg) was administered i.p.
once every other day for two weeks in the treatment
group. As described above, two independent experi-
ments were performed for each treatment with eight
mice per group, and the CG, PG, SG, and Model groups
were also given on the same schedule. On day 15, eight
mice from each group were anaesthetized and sacrificed
by picking off the eyeballs, and their blood sample, liver,
brain were quickly harvested. All tumor, thymus, spleen
and lung were also removed and weighted for the asses-
sion of antitumor and antimetastic activities and side-
effects. Invasive metastases to the lung were observed
manually. The rest of mice were used as assessing the
survival time.
Histological examination and immunohistochemistry
staining
For histopathology studies, all tumors were washed by
normal saline, fixed by 10 % paraformaldehyde in phos-
phate buffer saline, successively dehydrated in solutions
containing an increasing percentage of ethyl alcohol (70,
80, 95 and 100 %), embedded in paraffin under a vac-
uum, cut into 5 μm-thick sections, deparaffinized in
histo-clear agent, and stained with Harris hematoxylin-
eosin (HE staining).
For immunohistochemical staining, lung tissues in
C57BL/6 mouse were fixed for at least 24 h by Bouin
soultion. Lung tissue sections of 5 μm-thick were dried
overnight at 65 °C and deparaffinized in histo-clear. The
sections were rehydrated through graded alcohols into
water. After rehydrating, antigen retrieval was carried out
by heating for 20 min at 100 °C in 10 mM citrate buffer
(pH 6.0). Endogenous peroxidase activity was blocked with
3 % H2O2 in methanol for 10 min at room temperature
and non-specific binding of reagents was quenched by
10 % normal goat or rabbit serum. After rinsing with dis-
tilled water for 5 min, the sections were incubated at 4 °C
to stay overnight with primary anti-mouse HMB45 mono-
clonal antibody. The sections were rinsed with PBS again
for 2 min, and then were incubated at 37 °C for 30 min
with horseradish peroxidase-conjugated goat anti-mouse
IgG secondary antibody. After washing by PBS, the sec-
tions were stained using a DAB kit and observed under
microscope. Appropriate positive and negative controls
without primary antibody were included.
Analysis of the antioxidant endogenous enzyme GSH-Px
The defense effect of CFCT on antioxidant-related en-
dogenous enzyme GSH-Px was investigated. Blood sam-
ples were collected from the orbital venous plexuses of the
mice under anesthesia. The brains and livers were rapidly
excised and thoroughly washed to clear off blood.
These organs were immediately transferred to ice-cold
saline and homogenized (10 %) in cold saline (about 4 °C).
The blood and homogenate tissues were centrifuged at
3000 × g and 4 °C for 20 min. GSH-Px in the supernatants
was assessed using the respective detection kits as previ-
ously described [9].
Statistical analysis
For each measured drug concentration, there were five to
eight identical wells in the 96-well culture plates. All ex-
periments were performed at least three times. The ex-
perimental data were statistically analyzed using the SPSS
(version 13.0) software, and the data were expressed as the
means with their corresponding standard errors. When
appropriate, statistical significance was analyzed using a
two-tailed Student’s t-test. Differences were considered
statistically significant if P < 0.05.
Results
Cytotoxic activity of CFCT against human cancer cells in
vitro
The cytotoxic activities of CFCT against two different can-
cer cell lines, i.e. human lung carcinoma A549 cells and
human gastric carcinoma SGC-7901 cells, were displayed
in Fig. 1. CFCT exerted potent cytotoxic activities in a
dose-dependent manner at the dose range from 1.9 to
250.0 μg/mL after 48 h of exposure (Fig. 1a). The IC50
values of CFCT against cancer cells were calculated to be
30.2 ± 2.6 and 65.7 ± 5.3 μg/mL for A549 and SGC-7901
cells, respectively. Therefore, the A549 cells showed about
two-fold sensitivity toward CFCT in comparision to SGC-
7901 cells. As shown in Fig. 1b, the cytotoxic activities of
CFCT against A549 cancer cells presented approximately
in a time-dependent manner within the time range tested
at a dosage of 40 μg/mL, but a non-time-dependent man-
ner for SGC-7901 cells.
Antitumor effect of CFCT in S180 tumor-bearing KM mice
As shown in Table 1, the tumor weight of HG, MG, and
CG groups was decreased significantly compared with
that of the model group. However, no significant differ-
ence of tumor weight was observed between LG and
model groups. The inhibitory ratio of HG, MG and CG
groups was 57.9 ± 8.9 %, 33.6 ± 12.8 %, and 69.4 ± 9.7 %
(Fig. 2a), respectively, which presented significant differ-
ences in comparison with model control (P < 0.01). Fur-
thermore, the inhibitory ratio of the positive control
(56.1 ± 9.1 %) was also lower than both HG and CG
groups. Further histopathological analysis of tumor tis-
sue by HE staining showed a large number of necrotic
cancer cells or tissues (blue arrow denote necrotic cells)
in the HG, MG and CG groups (Fig. 2b). Accordingly,
these data indicated that CFCT could significantly inhibit
tumor growth in S180 tumor-bearing KM mice.
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Antitumor effect of CFCT in melanoma B16F10-bearing
C57BL/6 mice
CFCT could inhibit the tumor growth of murine metastatic
melanoma B16F10-bearing mice in comparison with the
model group, especially in the HG and CG groups (Table 2).
As shown in Fig. 3a, it resulted in more than 30 % inhib-
ition in both HG group (P < 0.05) and CG group (P < 0.01)
compared with the model group. However, no significant
difference of tumor weight was observed between LG group
and the model group. Further histopathological analysis of
tumor tissue with HE staining displayed a large number of
necrotic cancer cells or tissues (blue arrow denote necrotic
cells) in the HG and CG groups (Fig. 3b). Therefore, these
data suggested that CFCT could moderately inhibit tumor
growth in B16F10-bearing C57BL/6 mice.
Immune organ index and survival prolongation of
tumor-bearing mice after CFCT treatment
Thymus and spleen are the primary immune organs and
directly affect the organism’s immune function [15]. The
Fig. 1 Cytotoxicity of CFCT against human lung carcinoma A549 cells and human gastric carcinoma SGC-7901 cells. a A549 cells and SGC-7901
cells treated with different concentrations of CFCT for 48 h; b A549 cells and SGC-7901 cells treated with CFCT (40 μg/mL) for a different period
(8–76 h). Data were shown as mean ± SD (n = 3)
Table 1 Effects of CFCT on tumor weight and immune organ indices on day 8 in S180 tumor-bearing KM mice
Group Dosage (mg/kg) Tumor weight (g) Spleen index (mg/g) Thymus index (mg/g)
Model ─ 0.97 ± 0.19 4.683 ± 1.149 2.994 ± 0.702
PG 20.0 0.42 ± 0.09** 5.600 ± 0.667 3.060 ± 0.397
SG ─ 0.91 ± 0.23 4.484 ± 1.064 2.611 ± 0.375
HG 100.0 0.41 ± 0.09** 6.288 ± 0.983* 2.512 ± 0.190*
MG 50.0 0.64 ± 0.12** 5.750 ± 0.907* 2.230 ± 0.293**
LG 20.0 0.83 ± 0.26 4.864 ± 0.584 2.587 ± 0.230*
CG (LG + PG) 0.30 ± 0.09** 5.751 ± 1.146* 2.723 ± 0.410
Values are mean ± SD (n = 8). **P < 0.01, *P < 0.05 vs. model control group. All groups as described with Fig. 2
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Fig. 2 Antitumor effect of CFCT in S180 tumor-bearing KM mice. a Inhibitory rate in treatment groups. Values were expressed as mean ± SD
(n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average tumor
weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues. **P < 0.01 vs.
model group. Model group, mice were treated with olive oil at the same volume as the CFCT treatment group; PG, mice were treated with
cytoxan (20 mg/kg); SG, mice were treated with saline at the same volume as the CFCT treatment group; HG, mice were treated with CFCT
(100 mg/kg); MG, mice were treated with CFCT (50 mg/kg); LG, mice were treated with CFCT (20 mg/kg); CG, mice were treated with cytoxan
(20 mg/kg) and CFCT (20 mg/kg)
Table 2 Effects of CFCT on tumor weight and immune organ indices on day 15 in melanoma B16F10-bearing C57BL/6 mice
Group Dosage (mg/kg) Tumor weight (g) Spleen index (mg/g) Thymus index (mg/g)
Model ─ 2.07 ± 0.29 9.648 ± 1.992 1.133 ± 0.288
PG 20.0 1.04 ± 0.48** 8.067 ± 1.300 1.955 ± 0.460**
SG ─ 2.12 ± 0.31 9.152 ± 1.783 0.954 ± 0.291
HG 100.0 1.42 ± 0.47* 6.858 ± 1.321* 1.800 ± 0.521*
MG 50.0 1.62 ± 0.26* 7.180 ± 1.437* 1.603 ± 0.427*
LG 20.0 1.76 ± 0.25 7.080 ± 2.369* 1.164 ± 0.390
CG (LG + PG) 1.01 ± 0.32** 8.284 ± 1.806 1.136 ± 0.466
Values are mean ± SD (n = 8). **P < 0.01, *P < 0.05 vs. model control group. All groups as described with Fig. 2
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effects of CFCT on the thymus index and spleen index of
both tumor-bearing mouse models were shown in Table 1
and Table 2. Compared to the model control group, the
spleen index of KM mice and the thymus index of C57BL/
6 mice in the MG and HG groups were significantly in-
creased (P < 0.05). However, CFCT at all dosages tested
had obvious inhibitory effects on the thymus index of KM
mice and the spleen index of C57BL/6 mice (P < 0.05).
The beneficial effects of CFCT on tumor-bearing mouse
models were also reflected in the survival time. Survival
times of the tumor-bearing mice in the MG, HG and CG
groups were significantly prolonged for both tumor-
bearing models compared with the model control group
(Table 3, Table 4, and Fig. 4, P < 0.01). The extension rate
of lifespan of HG group was slightly lower than that of
positive control group PG, but the extension rate of life-
span of CG group was higher than that of PG group
(Table 3, Table 4, and Fig. 4).
Antimetastatic activity of CFCT in melanoma
B16F10-bearing C57BL/6 mice
Malignant melanoma, with high metastasis risk, often
transfers to the lung tissue in C57BL/6 mice by blood me-
tastasis, and is commonly used as a model of tumor me-
tastasis [16]. Histopathological section of tumor-bearing
C57BL/6 mice lung tissue with HE staining showed obvi-
ously metastatic foci of melanoma B16F10 (blue arrow) in
the model and LG groups (Fig. 5), particularly in the
model group. But metastatic foci were not observed in
other groups.
HMB45, molecular weight of 7000 kDa, is a specific pro-
tein marker for melanoma cells, and mainly distributed in
the cytoplasm [17]. Further, the expression of HMB45 in
the lung tissue of tumor-bearing C57BL/6 mice was
assessed by the immunohistochemical staining method.
As shown in Fig. 6, the cytoplasm was basically dyed clay-
bank (red arrow), which indicated the aggregation of
Fig. 3 Antitumor effect of CFCT in melanoma B16F10-bearing C57BL/6 mice. a Inhibitory rate in treatment groups. Values were expressed as
mean ± SD (n = 8). The inhibitory ratio = (the average tumor weight of model group - the average tumor weight of treatment group)/the average
tumor weight of model group × 100 %; b Representative HE staining sections from different groups. Blue arrows denote necrotic tissues.
*P < 0.05, **P < 0.01 vs. model group. All groups as described with Fig. 2
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HMB45 positive cells in the solid tumor tissue (TG) of
model group. Consistently, a clay-bank lump (red arrow),
meaning small metastatic foci, was found in the lung tis-
sue of model group, and it was different from the sur-
rounding normal lung tissue. Only a few HMB45 positive
cells were observed in the lung tissue of LG group, and
they were not found in the MG, HG and CG groups. In
addition, the HMB45 positive cells were more spread out
in comparison to the model group and metastatic foci
were not found in the lung tissue of solvent group (SG).
Based on the above results of HE and HMB45 immu-
nohistochemistry staining, the HG and MG groups of
CFCT could effectively inhibit the lung metastasis of ma-
lignant melanoma B16F10 in C57BL/6 mice.
Effect of CFCT on the GSH-Px activity in melanoma
B16F10-bearing C57BL/6 mice
Studies have shown that enhancement of antioxidant
capacity is one of the main action mechanism of anti-
cancer drugs [18]. In the present study, the effects of
CFCT on the activities of endogenous antioxidant en-
zyme GSH-Px in the blood, brain, and liver tissues were
investigated in melanoma B16F10-bearing C57BL/6 mice
(Fig. 7). Compared with the model group, CFCT at
100 mg/kg (HG group) evidently enhanced the enzyme
activities of GSH-Px in all tested tissues (P < 0.05 or P <
0.01). In addition, the MG (P < 0.05) and CG (P < 0.01)
groups of CFCT only increased the enzyme activities of
GSH-Px in blood.
Discussion
Cordyceps is a potential source for the discovery of anti-
cancer drugs. It has been well documented that Cordy-
ceps-derived extracts and/or compounds showed potent
inhibitory activities against different cancer cell lines in
vitro through different mechanisms as reviewed previously
[6]. However, in vitro methods are susceptible to false-
positive and false-negative results [19]. Therefore, it is em-
phasized that antitumor efficacy testing in rodents should
be used to predict the possible clinical response. Until
now, only a few of Cordyceps-derived polysaccharides
and/or water extracts have been investigated for their
antitumor potentials in the tumor-bearing animal
models [20–22], and in vivo antitumor effects of Cordy-
ceps-derived lipophlic extracts and/or chemical entities
have yet to be elucidated.
This study showed that CFCT, a lipophlic extract of
C. taii, possessed moderate cytotoxicity against human
cancer cell lines in vitro, and furthermore it could re-
markably inhibit tumor growth in S180 tumor-bearing
KM mice and melanoma B16F10-bearing C57BL/6 mice.
CFCT also prolonged the survival time and increased
the survival rate in both models. The histopathological
results indicated that each administration group of
CFCT could effectively inhibit the tumor growth and nu-
clear fission, and lead to necrosis of tumor tissue, espe-
cially for the HG and CG groups. It is known that both
the innate and the adaptive immune systems are active
against cancers [23]. Thymus is a top central immune
Table 3 Effect of CFCT on survival rate in S180 tumor-bearing KM mice
Group Dosage (mg/kg) Survival time (d) Survival prolongation rate (%)
Model ─ 33.2 ± 1.7 ─
PG 20.0 42.5 ± 1.4** 26.39 ± 0.82**
SG ─ 34.1 ± 1.7 1.49 ± 0.11
HG 100.0 42.1 ± 1.6** 25.28 ± 0.14**
MG 50.0 39.1 ± 1.1** 16.36 ± 1.68**
LG 20.0 36.4 ± 1.2 8.18 ± 1.49
CG (LG + PG) 42.9 ± 2.0** 27.51 ± 0.80**
Values are mean ± SD (n = 8). **P < 0.01 vs. model control group. All groups as described in Fig. 2
Table 4 Effect of CFCT on survival rate in B16-bearing C57BL/6 mice
Group Dosage (mg/kg) Survival time (d) Survival prolongation rate (%)
Model ─ 32.13 ± 1.46 ─
PG 20.0 38.75 ± 1.04** 20.62 ± 1.32**
SG ─ 32.38 ± 1.41 0.78 ± 0.16
HG 100.0 38.13 ± 1.55** 18.68 ± 0.30**
MG 50.0 35.50 ± 1.69** 10.51 ± 0.72**
LG 20.0 33.00 ± 2.14 2.72 ± 2.12
CG (LG + PG) 39.13 ± 1.13** 21.79 ± 1.03**
Values are mean ± SD (n = 8). **P < 0.01 vs. model control group. All groups as described in Fig. 2
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organ, and spleen is one of the biggest peripheral im-
mune organs [24, 25]. The viscera indices of thymus and
spleen are recognized as the preliminary indicators to re-
flect the body’ immune function [15]. Previous studies
have suggested that the crude extract of Cordyceps could
inhibit the tumor growth associated with the elevated
thymus and/or spleen index [26]. In this study, the
thymus index of C57BL/6 mice and the spleen index of
KM mice were increased when treated with CFCT of
100 mg/kg and 50 mg/kg, respectively (Table 1 and Table 2).
The results imply that CFCT might have different immune
regulation mechanisms on two mouse models. The in-
creased thymus index suggested that CFCT could potenti-
ate cell-mediated immunity of C57BL/6 mice, and the
increased spleen index implied that CFCT could enhance
humor-mediated immunity of KM mice. However, a bit
confusing fact is that the spleen index of C57BL/6 mice
and the thymus index of KM mice were slightly decreased
under treatment with CFCT. Because the immune organ
index is just a superficial indicator of immune function,
the precise effects of CFCT on immune system need fur-
ther investigation.
The presence of metastasis is the major cause of can-
cer mortality in millions of cancer patients, and it is ur-
gently required to develop new anticancer agents with
antimetastatic activities. Melanoma is one of the most
aggressive skin cancers with a high metastatic potential,
and it is difficult to be curbed [27]. In most cases, the
lung is the first organ that tumor cells detaching from
primary tumors encounter, making it a major site for
tumor metastasis. In this study, the lung metastasis of
melanoma B16F10 cells was effectively inhibited by
CFCT alone and in combination with CTX, but its
mechanism of action remained unclear. One group re-
ported that the combination of chemotherapeutic agent
methotrexate and water extract of C. sinensis (WECS)
Fig. 4 Survival prolongation of tumor-bearing models after CFCT treatment. a Survival time of S180 tumor-bearing KM mice; b Survival time of
melanoma B16F10-bearing C57BL/6 mice. Graph shows Kaplan-Meier survival curves for tumor-bearing mice treated with different groups. Survival
was significantly longer in LG-treated mice vs. model group (log-rank test, P < 0.05). Data were presented as mean ± SD (n = 8). All groups were
the same as described in the legends of Fig. 2
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could inhibit the hematogenic lung metastasis in me-
lanoma B16-BL6-bearing C57BL/6 J mice [28]. WECS
could also reduce the hepatic metastasis of melanoma
B16-F0 cells in C57BL/6Cr mice, and its mechanism of
antimetastatic action was associated with reducing the
hepatocyte growth factor, and accelerating the secretion
of tissue inhibitor of metalloproteinase-1 [29, 30]. An-
other group demonstrated that exopolysaccharide of C.
sinensis inhibited tumor growth and metastasis in the
lungs and livers of B16 melanoma-bearing mice by redu-
cing c-Myc, c-Fos, and vascular endothelial growth fac-
tor receptor (VEGF) expression levels [31]. Here VEGF
Fig. 5 Pathological changes of lung tissue from B16F10-bearing C57BL/6 mice by HE staining after administration. Blue arrows denote metastasis.
All groups as described in Fig. 2
Fig. 6 Effects of CFCT on immunohistochemistry in lung tissue from melanoma B16F10-bearing C57BL/6 mice. Light micrograph of HMB45-
positive cells (original magnification × 400) stained by the anti-mouse HMB45 mouse monoclonal antibody. Red arrows denote HMB45 protein.
TG: solid tumor tissue of model group. Other groups as described in Fig. 2
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is a central molecule involved in the angiogenesis and
metastasis and regarded as a cancer therapeutic target of
the angiogenesis and metastasis [32, 33]. Interestingly,
Ruma et al. recently observed that C. militaris extract
could remarkably suppress melanoma growth by down-
regulating VEGF expression and inducing the cell apop-
tosis [21]. This work implies that the anticancer and
antimetastatic mechanisms of CFCT are possibly associ-
ated with the anti-angiogenicity and apoptosis induction.
It is well known that oxidative stress is involved in a
variety of pathological processes, such as cancer, neuro-
degenerative diseases, ageing, and cardiovascular dis-
eases [34, 35]. The role of redox signaling in cancer
progression is well accepted. In general, a higher level of
reactive oxygen species (ROS) is essential for cancer cell
survival, proliferation, and metastasis via the regulation
of redox signaling. H2O2 can function as a signaling
molecule in tumor angiogenesis by inhibiting tyrosine
phosphatase activity in growth factor signaling transduc-
tion [36, 37]. Therefore, therapeutic strategies aimed at
removal of free radicals, especially H2O2, might be a rea-
sonable choice for the treatment and prevention of can-
cer. Recently many extracts and products of Cordyceps
have been shown to have significant antioxidant properties
[38]. Polysaccharides from C. sinensis and C. militaris pos-
sessed strong antioxidant activities such as scavenging
free-radicals, inhibiting lipid peroxidation, chelating metal
ion, etc. [39, 40]. Our previous studies demonstrated that
polysaccharides of C. jiangxiensis and C. taii possessed
antioxidant activities in vitro and in vivo [9, 41]. The facts
suggested that Cordyceps may be a promising source of
antioxidants or antioxidant compounds. In the case of
B16F10-bearing mice treated with CFCT of 100 mg/kg,
the activities of GSH-Px, one of primary antioxidant
enzyme that converts glutathione to oxidized glutathi-
one and metabolizes H2O2 and lipid hydroperoxides
into harmless products, were found to be significantly
increased in blood, brain and liver tissues compared to
the model mice (Fig. 7). Our data indicate that the an-
titumor activity of CFCT could be due to, at least in part,
its ability to enhance the GSH-Px activity of organisms.
Therefore, the antioxidant properties of CFCT in vitro and
in vivo and whether the tumor inhibition of CFCT is
linked to antioxidation are to be addressed here.
Previous studies demonstrated that the antitumor ef-
fective components of water extracts in C. sinensis and
C. militaris included cordycepin and polysaccharide
[21, 31, 42]. Chemical compositions of lipophlic extracts
in Cordyceps species are more complicated and diver-
sified. The definite antitumor effect of CFCT in vivo
provided a substantial foundation for the further devel-
opment of new chemopreventive lead compounds from
C. taii. Recently, a bioassay-guided separation of CFCT
was conducted by combining silica gel column chroma-
tography and semipreparative high-performance liquid
chromatography with SRB assay by our group [43]. Al-
though cordycepin, the most well-known anticancer
substance in Cordyceps, was not detected in C. taii
[44], three known compounds - helvolic acid, cytocha-
lasin C and zygosporin D, and three new cytochalasin
derivatives, were isolated and identified from CFCT
[13, 43]. Furthermore, we found that cytochalasin C,
zygosporin D and three new cytochalasin derivatives
displayed remarkable cytotoxicity against both lung
cancer cell lines 95-D and A-549 in vitro, while no
cytotoxic effect to human normal lung cells MCR-5.
These findings indicated that those five compounds
had excellent selectivity between normal and cancer
cells, and their molecular mechanism of anticancer de-
served an in-depth study [43]. Helvolic acid, a fusidane
skeleton triterpenic acid with antimicrobial activity,
was identified from Cordyceps species for the first time,
and was also verified that it had potent cytotoxic ac-
tivity against various human cancer cell lines [13].
Through these researches, the concrete effective com-
ponents of CFCT could be understood at least partially,
which is important to our searching for cancer chemo-
preventive compounds from the medicinal mushroom
C. taii.
Conclusion
CFCT was found to have notable antitumor and antime-
tastatic activities in vivo. The possible mechanism of the
anticancer effect of CFCT may be related to its anti-
proliferation, antioxidant, and immunoregulatory effects,
but a further investigation is required. To our know-
ledge, this is the first report on antitumor and antimeta-
static activities by the lipophlic extract of C. taii.
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